DNA methylation and clinical response to antidepressant medication in major depressive disorder: A review and recommendations

•Research into the role that epigenetic mechanisms play in Major Depressive Disorder has grown rapidly over the last decade.•Studies examining epigenetic mechanisms in psychiatric treatment response are rapidly emerging.•We examine articles investigating DNA methylation and clinical antidepressant r...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience letters 2018-03, Vol.669, p.14-23
Main Authors: Lisoway, Amanda J., Zai, Clement C., Tiwari, Arun K., Kennedy, James L.
Format: Article
Language:English
Subjects:
Antidepressant response
Antidepressive Agents - therapeutic use
Brain-Derived Neurotrophic Factor - genetics
Depression - drug therapy
Depression - genetics
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - genetics
DNA Methylation
Epigenesis, Genetic
Epigenomics
Humans
Interleukin-11 - genetics
Major depressive disorder
Pharmaco-epigenetics
Pharmacological treatment
Psychiatry
Serotonin Plasma Membrane Transport Proteins - genetics
Treatment response
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Research into the role that epigenetic mechanisms play in Major Depressive Disorder has grown rapidly over the last decade.•Studies examining epigenetic mechanisms in psychiatric treatment response are rapidly emerging.•We examine articles investigating DNA methylation and clinical antidepressant response in Major Depressive Disorder.•Conclusions include a summary of current limitations and suggestions for future directions. Antidepressant medications are the most common treatment for major depression and related disorders. Pharmacogenetic studies have demonstrated that response to these medications is associated with genetic variation. While these studies have been invaluable they have yet to explain why a significant number of patients do not respond to their initial medication. The epigenetic modification known as DNA methylation has recently been studied in the context of antidepressant treatment response. As such, the purpose of this article is to review the advances made in the relatively new field of pharmaco-epigenetics of antidepressant response. We included all published articles examining DNA methylation in association with antidepressant treatment response in Major Depressive Disorder from April 2006 to June 2016 using the PubMed, Medline, PsychInfo and Web of Science databases. At the present time, although original articles are limited, epigenetic modifications of SLC6A4, BDNF, and IL11 genes are showing promising results as biomarkers for prediction of antidepressant response. However, research methods and results are heterogeneous and additional studies are required before results are generalizable. At the end of this review we provide recommendations for study design and analytic approaches.
ISSN:0304-3940
1872-7972
DOI:10.1016/j.neulet.2016.12.071